TAB2 Antibody - #AF4635

Fig. 7: RGS16 disrupt TRAF6-TAB2 interaction and inhibit TAK1-JNK/p38 MAPK activation. A RNA-seq was performed on Caco-2 cells transfected with Ctrl and shRGS16 vectors. B Volcano map showing DEGs in above two groups. The red dots represent up-regulated DEGs, and the blue dots represent down-regulated DEGs. The gray dots represent genes without significant differences in expression. C KEGG enrichment analysis was performed between SW480 cells transfected with RGS16 shRNA vector and the control group. D the Caco-2 and SW480 cells were transfected with control and RGS16 siRNA for 48 h, and then treated with DMSO or Takinib for 8 h. The RGS16 and the activation of indicated protein were examined by Western blotting. E The whole cell extracts (input) were immunoprecipitated with anti-IgG or anti-RGS16 antibody plus protein A/G beads. Components in the RGS16 complex were examined by Western blotting. F The Caco-2 and SW480 cells were transfected with control and RGS16 siRNA for 48 h. Then the whole cell extracts (input) were immunoprecipitated with anti-IgG or anti-TRAF6 antibody plus protein A/G beads. Components in the TRAF6 complex were examined by Western blotting. G The Caco-2 and SW480 cells were transfected with Flag-RGS16 as indicated for 48 h. Then the whole cell extracts (input) were immunoprecipitated with anti-IgG or anti-TRAF6 antibody plus protein A/G beads. Components in the TRAF6 complex were examined by Western blotting. H The Caco-2 and SW480 cells were transfected with Flag-RGS16 as indicated for 48 h. The RGS16 and the activation of indicated protein were examined by Western blotting. One representative experiment of three is shown.